PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from argenx US, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.


Faculty/Planner
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.


Faculty/Planner
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.

Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.
Data Safety Monitoring Board for Sanofi.


Co-Chair/Planner
Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.
Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UDJ865. CME credit will be available until November 20, 2024.

Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Eric Marsh, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc. and Stoke Therapeutics.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Curaleaf, Inc.; Epygenix Therapeutics, Inc.; Marinus Pharmaceuticals, Inc.; Stoke Therapeutics; and Takeda Pharmaceutical Company Limited.


Faculty/Planner
David N. Lieberman, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; and Jazz Pharmaceuticals, Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.

Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.


Faculty/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.

Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

Atopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.

Chair
Amy S. Paller, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Patient Advocate
Kacey Jenkins


In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Amy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.
Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.


Patient Advocate/Planner
Kacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NQQ865. CME credit will be available until November 9, 2024.

From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Alan K. Percy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.

Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Claudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZQX865. CME credit will be available until November 2, 2024.

Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosures
Philip J. Mease, MD, MACR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; ACELYRIN Inc.; Aclaris Therapeutics, Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Galapagos NV; Gilead Sciences, Inc.; GlaxoSmithKline; Inmagene; Janssen Pharmaceuticals, Inc.; Lilly; MoonLake Immunotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Ventyx Biosciences, Inc.; and XinThera.
Grant/Research Support from AbbVie.; ACELYRIN Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speaker for AbbVie; Amgen; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc.


M.E. Beth Smith, DO, MCR, FACP, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.

Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Hiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.
Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.
Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.


Co-Chair/Planner
Prof. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.
Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.

Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.

In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn’t watch the live event, this on-demand version is available now!

Co-Chair & Moderator
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
The Hamilton Group Behavioral Health LLC
Las Vegas, Nevada

Co-Chair & Presenter
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Rasmussen University
Bloomington, Minnesota

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sage Therapeutics and Biogen.

Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).
Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).


Co-Chair/Planner
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Point of Care Network (POCN).
Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.